Latest News and Press Releases

DUBLIN, Ireland, and Boston MA, July 28, 2021, Amryt (Nasdaq: AMYT, AIM: AMYT), a global, commercial-stage biopharmaceutical company dedicated to acquiring, developing and commercializing novel...

Amryt to Report Q2 2021 Results and Host Conference Call & Webcast on August 6 DUBLIN, Ireland, and Boston MA, July 12, 2021, Amryt (Nasdaq: AMYT, AIM: AMYT), a global, commercial-stage...

Publication of Circular to Amryt Shareholders in relation to the acquisition of Chiasma, Inc., and posting of Annual Report and Notices of General Meetings DUBLIN, Ireland, and Boston MA, 28 June...

Amryt Pharma Announces Filing of Preliminary Registration Statement on Form F-4 in Connection with Its Proposed Acquisition of Chiasma, Inc. DUBLIN, Ireland, and Boston MA, June 15, 2021, Amryt...

FDA confirms NDA for Oleogel-S10 will not require an Advisory Committee Meeting DUBLIN, Ireland, and Boston MA, June 7, 2021, Amryt (Nasdaq: AMYT, AIM: AMYT), a global, commercial-stage...

FDA Grants Priority Review for New Drug Application for Oleogel-S10 for the Treatment of Epidermolysis Bullosa PDUFA date of November 30, 2021 set for Oleogel-S10 DUBLIN, Ireland, and Boston MA,...

Amryt Announces FDA Acceptance of New Drug Application for Oleogel-S10 for the Treatment of Epidermolysis Bullosa DUBLIN, Ireland, and Boston MA, June 2, 2021, Amryt (Nasdaq: AMYT, AIM: AMYT), a...

Amryt Reports Record Q1 2021 Financial and Operating Results 8.7% YoY revenue growth in the quarter to $48.4M 16.5% YoY underlying revenue growth excluding the impact of a LATAM periodic order in...

- Combined business will have three approved commercial products, lomitapide (Lojuxta®/Juxtapid®), metreleptin (Myalept®/ Myalepta®), octreotide (MYCAPSSA®) and a robust clinical pipeline - Lead...

DUBLIN, Ireland, and Boston MA, April 15, 2021, Amryt (Nasdaq: AMYT, AIM: AMYT), a global, commercial-stage biopharmaceutical company dedicated to acquiring, developing and commercializing novel...